Innate sensors of influenza virus: Clues to developing better intranasal vaccines

Expert Review of Vaccines

Volumn 7, Issue 9, 2008, Pages 1435-1445

  Ichinohe, Takeshi ^a   Iwasaki, Akiko ^a   Hasegawa, Hideki ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Adaptive immune response; Adjuvant; IL 1 ; Inflammasome; Influenza; Innate immune response; Intranasal vaccine; NALP3; NOD like receptor; RIG 1 like receptor; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 4; GAMMA INTERFERON; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NONSTRUCTURAL PROTEIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; INFECTION RESISTANCE; INFLUENZA VACCINATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; RECEPTORS, IMMUNOLOGIC;

EID: 55849132494     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.9.1435     Document Type: Review

References (130)

1. Smidt MH, Stroink H, Bruinenberg JF, Peeters M. Encephalopathy associated with influenza A. Eur. J. Paediatr. Neurol. 8(5), 257-260 (2004).
2. Wada N. Influenza-associated encephalopathy. Nippon rinsho 62(Suppl. 5) 456-461 (2004).
3. Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Eng. J. Med. 352(4), 333-340 (2005). • First report of human-to-human transmission of avian influenza A (H5N1).
4. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11(10), 1515-1521 (2005).
5. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
6. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nature Med. 8(9), 950-954 (2002).
7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413(6857), 732-738 (2001). • First demonstrated that mammalian Toll-like receptor (TLR)3 recognizes dsRNA, poly(I:C) and induces the production of type I interferons.
8. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663), 1529-1531 (2004).
9. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101(15), 5598-5603 (2004).
10. Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J. Immunol. 173(11), 6882-6889 (2004).
11. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80(10), 5059-5064 (2006).
12. Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314(5801), 997-1001 (2006). •• Demonstrated that 5′-triphosphagte ssRNA is recognized by retinoic acid inducible gene I (RIG-I). Host RNA is capped, and interferon-inducing activity of the RNA was lost by capping of triphosphate ssRNA.
13. Bracci L, Canini I, Puzelli S et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23(23), 2994-3004 (2005).
14. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
15. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198(3), 513-520 (2003).
16. Asselin-Paturel C, Boonstra A, Dalod M et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2(12), 1144-1150 (2001).
17. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315(5817), 1398-1401 (2007).
18. Crozat K, Beutler B. TLR7: a new sensor of viral infection. Proc. Natl Acad. Sci. USA 101(18), 6835-6836 (2004).
19. Reis e Sousa C. Immunology. Eating in to avoid infection. Science 315(5817), 1376-1377 (2007).
20. Iwasaki A. Role of autophagy in innate viral recognition. Autophagy 3(4), 354-356 (2007).
21. Lee HK, Iwasaki A. Autophagy and antiviral immunity. Curr. Opin. Immunol. 20(1), 23-29 (2008).
22. Kumagai Y, Takeuchi O, Kato H et al. Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses. Immunity 27(2), 240-252 (2007). • Demonstrated that IFN-α-producing cells are different depending on the route of infection. Alveolar macrophages produced IFN-α to local lung infecton of the Newcastle disease virus infection.
23. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J. Infect. Chemother. 14(2), 86-92 (2008).
24. Guo Z, Chen LM, Zeng H et al. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am. J. Resp. Cell Mol. Biol. 36(3), 263-269 (2007).
25. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr, Garcia-Sastre A. Inhibition of retinoic acid-inducible gene I-mediated induction of β interferon by the NS1 protein of influenza A virus. J. Virol. 81(2), 514-524 (2007).
26. Opitz B, Rejaibi A, Dauber B et al. IFNβ induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell. Microbiol. 9(4), 930-938 (2007).
27. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5(7), 730-737 (2004). •• First identified RIG-I as an essential regulator for cytosolic dsRNA-induced signaling.
28. Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23(1), 19-28 (2005).
29. Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, MDA-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad. Sci. USA 101(49), 17264-17269 (2004).
30. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. MDA-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl Acad. Sci. USA 99(2), 637-642 (2002).
31. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and MDA5-mediated type I interferon induction. Nat. Immunol. 6(10), 981-988 (2005).
32. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 122(5), 669-682 (2005).
33. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005).
34. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol. Cell 19(6), 727-740 (2005).
35. Moore CB, Bergstralh DT, Duncan JA et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 451(7178), 573-577 (2008).
36. Tattoli I, Carneiro LA, Jehanno M et al. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-κB and JNK pathways by inducing reactive oxygen species production. EMBO Reports 9(3), 293-300 (2008).
37. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101-105 (2006). •• Demonstrated that RIG-I and melanoma differentiation-associated gene (MDA)5 recognize different RNA viruses and RNA structures by generating mice deficient in RIG-I and MDA5.
38. Gitlin L, Barchet W, Gilfillan S et al. Essential role of MDA-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459-8464 (2006).
39. Hornung V, Ellegast J, Kim S et al. 5′-triphosphate RNA is the ligand for RIG-I. Science 314(5801), 994-997 (2006). •• Demonstrated that 5′-triphosphagte ssRNA is recognized by RIG-I. Host RNA is capped, and interferon-inducing activity of the RNA was lost by capping of triphosphate ssRNA.
40. Yoneyama M, Onomoto K, Fujita T. Cytoplasmic recognition of RNA. Adv. Drug. Deliv. Rev. 60(7), 841-846 (2008).
41. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601-1610 (2008).
42. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454(7203), 523-527 (2008).
43. Saito T, Gale M Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 205(7), 1523-1527 (2008).
44. Koyama S, Ishii KJ, Kumar H et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179(7), 4711-4720 (2007).
45. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. 1(2), 135-145 (2001).
46. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5(10), 987-995 (2004).
47. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438(7066), 364-368 (2005).
48. McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J. Exp. Med. 205(7), 1635-1646 (2008).
49. - but not plasmacytoid dendritic cells. J. Exp. Med. 205(7), 1621-1634 (2008).
50. Heer AK, Shamshiev A, Donda A et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178(4), 2182-2191 (2007).
51. Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79(5), 2910-2919 (2005).
52. Ichinohe T, Tamura S, Kawaguchi A et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196(9), 1313-1320 (2007).
53. Ichinohe T, Kawaguchi A, Tamura S et al. Intranasal immunization with H5N1 vaccine plus poly I:poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect. 9(11), 1333-1340 (2007).
54. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev. 7(1), 31-40 (2007).
55. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 126(4), 659-662 (2006).
56. Werts C, Girardin SE, Philpott DJ. TIR, CARD and PYRIN: three domains for an antimicrobial triad. Cell Death Differ. 13(5), 798-815 (2006).
57. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 442(7098), 39-44 (2006).
58. Freche B, Reig N, van der Goot FG. The role of the inflammasome in cellular responses to toxins and bacterial effectors. Semin. Immunopathol. 29(3), 249-260 (2007).
59. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117(5), 561-574 (2004).
60. Chamaillard M, Hashimoto M, Horie Y et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4(7), 702-707 (2003).
61. Keller M, Ruegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132(5), 818-831 (2008).
62. Kuida K, Lippke JA, Ku G et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 β converting enzyme. Science 267(5206), 2000-2003 (1995).
63. Dinarello CA. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol, 20(5 Suppl. 27), S1-S13 (2002).
64. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5), 479-490 (2005).
65. Ting JP, Lovering RC, Alnemri ES et al. The NLR gene family: a standard nomenclature. Immunity 28(3), 285-287 (2008).
66. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957), 516-521 (2003).
67. Kanneganti TD, Ozoren N, Body-Malapel M et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440(7081), 233-236 (2006).
68. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081), 228-232 (2006).
69. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081), 237-241 (2006).
70. Sutterwala FS, Ogura Y, Szczepanik M et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24(3), 317-327 (2006).
71. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320(5876), 674-677 (2008).
72. Walev I, Klein J, Husmann M et al. Potassium regulates IL-1 β processing via calcium-independent phospholipase A2. J. Immunol. 164(10), 5120-5124 (2000).
73. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 β secretion: implications for inflammatory processes. Proc. Natl Acad. Sci. USA 101(26), 9745-9750 (2004).
74. Wewers MD. IL-1β: an endosomal exit. Proc. Natl Acad. Sci. USA 101(28), 10241-10242 (2004).
75. Fernandes-Alnemri T, Wu J, Yu JW et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14(9), 1590-1604 (2007).
76. Saleh M, Green DR. Caspase-1 inflammasomes: choosing between death and taxis. Cell Death Differ. 14(9), 1559-1560 (2007).
77. Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176(7), 3877-3883 (2006).
78. Kanneganti TD, Body-Malapel M, Amer A et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281(48), 36560-36568 (2006). • First to demonstrate that influenza virus activates the NALP3 inflammasome in conjunction with ATP.
79. Johnston JB, Barrett JW, Nazarian SH et al. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity 23(6), 587-598 (2005).
80. Muruve DA, Petrilli V, Zaiss AK et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452(7183), 103-107 (2008).
81. Vacheron F, Rudent A, Perin S, Labarre C, Quero AM, Guenounou M. Production of interleukin 1 and tumour necrosis factor activities in bronchoalveolar washings following infection of mice by influenza virus. J. Gen. Virol. 71 (Pt. 2), 477-479 (1990).
82. Hennet T, Ziltener HJ, Frei K, Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J. Immunol. 149(3), 932-939 (1992).
83. Pirhonen J, Sareneva T, Kurimoto M, Julkunen I, Matikainen S. Virus infection activates IL-1 b and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol. 162(12), 7322-7329 (1999).
84. Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 79(10), 6441-6448 (2005).
85. Stasakova J, Ferko B, Kittel C et al. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1b and 18. J. Gen. Virol. 86(Pt. 1), 185-195 (2005).
86. 2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest. 85(3), 739-745 (1990).
87. Behrens MD, Wagner WM, Krco CJ et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 111(3), 1472-1479 (2008).
88. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58(4), 195-207 (2005).
89. Asahi Y, Yoshikawa T, Watanabe I et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168(6), 2930-2938 (2002).
90. Hasegawa H, Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev. Vaccines 6(2), 193-201 (2007).
91. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69(2), 1339-1343 (1995).
92. Ito R, Ozaki YA, Yoshikawa T et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21(19-20), 2362-2371 (2003).
93. Tamura SI, Kurata T. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis. 53(3), 98-106 (2000).
94. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
95. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9), 4778-4782 (2000).
96. Ichinohe T, Nagata N, Strong P et al. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. J. Med. Virol. 79(6), 811-819 (2007).
97. Ichinohe T, Watanabe I, Tao E et al. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J. Med. Virol. 78(7), 954-963 (2006).
98. Kamijuku H, Nagata Y, Jiang X et al. Mechanism of NKT cell activation by intranasal coadministration of a-galactosylceramide, which can induce cross-protection against influenza viruses. Muc. Immunol. 1(3), 208-218 (2008).
99. Asahi-Ozaki Y, Itamura S, Ichinohe T et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8(12-13), 2706-2714 (2006).
100. Palese P. Making better influenza virus vaccines? Emerg. Infect. Dis. 12(1), 61-65 (2006).
101. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82(6), 740-744 (2007).
102. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug. Deliv. Rev. 51(1-3), 149-159 (2001).
103. Hartshorn KL, Crouch EC, White MR et al. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J. Clin. Invest. 94(1), 311-319 (1994).
104. Benne CA, Kraaijeveld CA, van Strijp JA et al. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J. Infect. Dis. 171(2), 335-341 (1995).
105. Hartshorn KL, Sastry K, Brown D et al. Conglutinin acts as an opsonin for influenza A viruses. J. Immunol. 151(11), 6265-6273 (1993).
106. Hartshorn KL, Sastry K, White MR et al. Human mannose-binding protein functions as an opsonin for influenza A viruses. J. Clin. Invest. 91(4), 1414-1420 (1993).
107. LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect. 3(2), 161-166 (2001).
108. Jia W, Li H, He YW. Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses. J. Immunol. 180(9), 6255-6261 (2008).
109. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60(3), 1068-1074 (1986).
110. Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol. 6(10), 995-1001 (2005).
111. Yamamoto M, Sato S, Hemmi H et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301(5633), 640-643 (2003).
112. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4), 461-470 (2001).
113. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4(10), 1009-1015 (2003).
114. Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. 23(6), 1217-1226 (2006).
115. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J. Immunol. 180(2), 683-687 (2008).
116. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A Phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J. Natl Cancer Inst. 57(3), 599-602 (1976).
117. Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 8(4), 599-604 (1994).
118. Ashkenazi S, Vertruyen A, Aristegui J et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J. 25(10), 870-879 (2006).
119. Vesikari T, Fleming DM, Aristegui JF et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118(6), 2298-2312 (2006).
120. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
121. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J. Infect. Dis. 144(5), 433-441 (1981).
122. Hall CB, Douglas RG Jr, Geiman JM, Meagher MP. Viral shedding patterns of children with influenza B infection. J. Infect. Dis. 140(4), 610-613 (1979).
123. Long CE, Hall CB, Cunningham CK et al. Influenza surveillance in community-dwelling elderly compared with children. Arch. Fam. Med. 6(5), 459-465 (1997).
124. Wright PF, Ross KB, Thompson J, Karzon DT. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N. Engl. J. Med. 296(15), 829-834 (1977).
125. Talon J, Salvatore M, O'Neill RE et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA 97(8), 4309-4314 (2000).
126. Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178(8), 5200-5208 (2007).
127. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25(18), 3554-3560 (2007).
128. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008).
129. World Health Organization. 30 April 2008. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO www.who.int/csr/disease/ avian_influenza/country/cases_table_2008_06_19/en/index.html
130. Health24.com. Nasal spray bird flu vaccine? www.health24.com/news/ Flu_Influenza/1-912,45493.asp